Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Valneva Se ADR (NQ: VALN ) 7.760 +0.110 (+1.44%) Streaming Delayed Price Updated: 11:05 AM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Valneva Se ADR < Previous 1 2 3 4 5 6 7 8 9 10 Next > Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session August 19, 2024 Via Benzinga ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday August 19, 2024 Via Benzinga Analyst Scoreboard: 8 Ratings For Valneva August 14, 2024 Via Benzinga What Analysts Are Saying About Valneva Stock July 22, 2024 Via Benzinga The Analyst Landscape: 6 Takes On Valneva June 24, 2024 Via Benzinga What Analysts Are Saying About Valneva Stock May 31, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Valneva May 08, 2024 Via Benzinga VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q2 2024 August 13, 2024 VALN stock results show that Valneva missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace 3 Promising Biotech Stocks You Can Pick Up for Less Than $10 July 29, 2024 Healthcare innovations are big business. That said, biotech stocks under $10 may offer a higher ceiling thanks to their low price. Via InvestorPlace Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026 July 18, 2024 Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease vaccine, VLA15. Participants will be monitored until the end of the 2025... Via Benzinga Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data May 13, 2024 Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil. Via Benzinga VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q1 2024 May 13, 2024 VALN stock results show that Valneva missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace What Analysts Are Saying About Valneva Stock March 22, 2024 Via Benzinga VALN Stock Earnings: Valneva Misses Revenue for Q4 2023 March 20, 2024 VALN stock results show that Valneva missed on revenue for the fourth quarter of 2023. Via InvestorPlace Expert Ratings for Valneva December 04, 2023 Via Benzinga Analyst Ratings for Valneva November 10, 2023 Via Benzinga National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday March 19, 2024 U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday March 08, 2024 U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday. Via Benzinga Topics Stocks Exposures US Equities Chikungunya Vaccine Maker Valneva Secures Non Dilutive Funding To Develop/Expand Its Clinical Pipeline February 05, 2024 Valneva sells FDA Priority Review Voucher for $103 million after FDA approval of Ixchiq, the world's first licensed chikungunya vaccine. Proceeds to boost R&D projects. Via Benzinga Exposures Product Safety Analyst Ratings for Valneva September 07, 2023 Via Benzinga McDonald's, Caterpillar And 3 Stocks To Watch Heading Into Monday February 05, 2024 With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: Via Benzinga Valneva Says Single Chikungunya Vaccine Shows Long-Lasting Antibody Response In Younger, Older Adults December 04, 2023 Valneva SE (NASDAQ: VALN) reported antibody persistence data 24 months after vaccination with a single dose of its chikungunya vaccine IXCHIQ, further supporting the anticipated long-term durability of... Via Benzinga FDA Approves World's First Mosquito-Borne Chikungunya Vaccine November 10, 2023 The FDA approved Valneva SE's (NASDAQ: VALN) Chikungunya single-dose vaccine in individuals Via Benzinga Exposures Product Safety Pfizer, Valneva's Tick-Borne Infection Shot: Companies Say 'Positive' Result For Lyme Disease Vaccine Candidate Booster September 07, 2023 Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) released pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, Via Benzinga 7 Unmatched Stocks: The Untapped Goldmines to Buy Now. August 24, 2023 Although these ideas for stocks with potential present high risk, they may also offer robust, even game-changing returns. Via InvestorPlace Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session August 14, 2023 Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration... Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session August 14, 2023 Via Benzinga AMC Entertainment, Nikola, Cleveland-Cliffs And Other Big Stocks Moving Lower In Monday's Pre-Market Session August 14, 2023 U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. Via Benzinga Top 5 Health Care Stocks That May Crash This Month June 22, 2023 The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. Via Benzinga Bavarian Nordic Beefs Up Chikungunya Vaccine Race With Valneva With Encouraging Late-Stage Trial Data June 20, 2023 Bavarian Nordic A/S's (OTC: BVNRY) phase 3 chikungunya virus vaccine (CHIKV VLP (PXVX0317) clinical trial has hit its primary endpoint in Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.